搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Medscape
3 小时
GLP-1 for Complex Cases: Breakthrough Therapies That Transform Patient Care
Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...
Rolling Out
1 天
Revolutionizing addiction treatment with GLP-1 agonists
Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.
3 小时
on MSN
Josh Gad reveals he had to stop taking weight-loss drug due to side effects: ‘Really ...
The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...
pharmaphorum
8 小时
Ozempic is first GLP-1 drug FDA-approved for kidney disease
Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...
Endocrinology Advisor
17 小时
Select GLP-1 Receptor Agonists Reduce Risk of CKD Progression, ESKD, and MACE
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
News Medical on MSN
9 天
Researchers create an atlas of health associations for GLP-1 receptor agonists
Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
21 小时
Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
来自MSN
8 天
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
来自MSN
1 天
LEXX: IRB Approval Clears Way for GLP-1 Study #5
LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...
IPWatchdog
1 天
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 ...
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈